4 results
2.1 Primary ObjectiveDescribing the association between Handscan optical scores, markers of inflammation (levels of CRP, serum IL-6) and clinical swollen joint score in three treatment groups with different pharmacokinetic modes of action for RA…
This study aims to test the hypothesis that zandelisib in combination with rituximab has better clinical activity and risk/benefit profile compared to standard 2nd line immunochemotherapy (R-CHOP/R-B) in subjects with relapsed FL or MZL. Primary…
Zie NL samenvatting
This study will evaluate the safety, tolerability, pharmacokinetics, and activity of XmAb24306 as a single agent (Phase Ia) or in combination with a checkpoint inhibitor targeting the PD-L1/PD-1 axis (Phase Ib) in patients with locally advanced or…